Francois Nader, MD Chairman of the Board Talaris

Francois Nader, MD

Francois Nader, MD, MBA currently serves as chair of Talaris Therapeutics (TALS), Benevolent AI (BAI)and Neurvati Neurosciences. He also serves as board director of Moderna (MRNA) and RING Therapeutics and as senior advisor to Blackstone Life Sciences.  Previously, Dr. Nader was Chief Executive Officer of NPS Pharma. During his tenure, Dr. Nader transformed NPS Pharma into a leading global biotechnology company focused on delivering innovative therapies to patients with rare diseases. Dr. Nader won the Ernst and Young National Life Science Entrepreneur of the Year® award in 2013.

Dr. Nader serves as trustee of the Lebanese American University and as board member of the American Task Force for Lebanon.

Before NPS, Dr. Nader was a venture partner at Care Capital. Prior, he served on the North America Leadership Team of Aventis and its predecessor companies holding a number of executive positions including senior vice-president, integrated healthcare markets and North America medical and regulatory affairs. Previously, he led the global commercial operations at the Pasteur Vaccins’ division of Rhone-Poulenc.

Dr. Nader is past chairman of BioNJ and as board chair of Acceleron Pharma (XLRN) acquired by Merck and Prevail Therapeutics (PRVL) acquired by Lilly. He served on the board director of Alexion (ALXN) acquired by Astra Zeneca, Clementia Pharmaceuticals (CMTA) acquired by IPSEN, Advanced Accelerator Applications (AAAP) acquired by Novartis, Baxalta (BXLT) acquired by Shire, and Noven (NOVN) acquired by Hisamitsu.

Dr. Nader earned his French Doctorate in Medicine from St. Joseph University (Lebanon) and his Physician Executive MBA from the University of Tennessee.